These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20299963)

  • 41. Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review.
    Wells MM; Roth LS; Marotta P; Levstik M; Mason AL; Bain VG; Chandok N; Aljudaibi BM
    Saudi J Gastroenterol; 2013; 19(5):223-9. PubMed ID: 24045596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin.
    Reau N; Hamzeh FM; Lentz E; Zhou X; Jensen D
    J Viral Hepat; 2012 Feb; 19(2):94-102. PubMed ID: 22239499
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of chronic hepatitis C virus infection. A study of best predictors for response].
    Vanegas NO; Román JL; Febles MH; Sánchez CG; Suárez JM; Martínez ER; Hernández LO; López MJ
    Rev Esp Quimioter; 2011 Dec; 24(4):198-203. PubMed ID: 22173189
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].
    Begovac J; Romih V
    Acta Med Croatica; 2009 Dec; 63(5):423-9. PubMed ID: 20198902
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure.
    Mandorfer M; Steiner S; Schwabl P; Payer BA; Aichelburg MC; Grabmeier-Pfistershammer K; Trauner M; Reiberger T; Peck-Radosavljevic M
    Wien Klin Wochenschr; 2016 Jun; 128(11-12):414-20. PubMed ID: 26659706
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV.
    Opravil M; Rodriguez-Torres M; Rockstroh J; Snoeck E; Chung RT; Tietz A; Torriani FJ
    HIV Clin Trials; 2012; 13(1):33-45. PubMed ID: 22306586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.
    Di Martino V; Richou C; Cervoni JP; Sanchez-Tapias JM; Jensen DM; Mangia A; Buti M; Sheppard F; Ferenci P; Thévenot T
    Hepatology; 2011 Sep; 54(3):789-800. PubMed ID: 21674553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.
    Dominguez S; Ghosn J; Cassard B; Melica G; Poizot-Martin I; Solas C; Lascaux AS; Bouvier-Alias M; Katlama C; Lévy Y; Peytavin G
    J Antimicrob Chemother; 2012 Jun; 67(6):1449-52. PubMed ID: 22396433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].
    Begovac J
    Acta Med Croatica; 2013 Oct; 67(4):351-9. PubMed ID: 24984336
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient.
    Payer BA; Reiberger T; Rutter K; Beinhardt S; Staettermayer AF; Peck-Radosavljevic M; Ferenci P
    J Clin Virol; 2010 Oct; 49(2):131-3. PubMed ID: 20709593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response.
    Zeuzem S; Rizzetto M; Ferenci P; Shiffman ML
    Antivir Ther; 2009; 14(2):143-54. PubMed ID: 19430089
    [TBL] [Abstract][Full Text] [Related]  

  • 52. No beneficial effects of amantadine in treatment of chronic hepatitis C patients.
    van Soest H; van der Schaar PJ; Koek GH; de Vries RA; van Ooteghem NA; van Hoek B; Drenth JP; Vrolijk JM; Lieverse RJ; Houben P; van der Sluys Veer A; Siersema PD; Schipper ME; van Erpecum KJ; Boland GJ
    Dig Liver Dis; 2010 Jul; 42(7):496-502. PubMed ID: 20018575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short Communication: CXCL12 rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy.
    Pineda-Tenor D; Jiménez-Sousa MA; Rallón N; Berenguer J; Soriano V; Aldámiz-Echevarria T; García-Álvarez M; Diez C; Fernández-Rodríguez A; Benito JM; Resino S
    AIDS Res Hum Retroviruses; 2016 Mar; 32(3):226-31. PubMed ID: 26499461
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients.
    Chung RT; Umbleja T; Chen JY; Andersen JW; Butt AA; Sherman KE;
    HIV Clin Trials; 2012; 13(2):70-82. PubMed ID: 22510354
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C.
    Morello J; Soriano V; Barreiro P; Medrano J; Madejón A; González-Pardo G; Jiménez-Nácher I; González-Lahoz J; Rodríguez-Novoa S
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1647-9. PubMed ID: 20100874
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.
    Mandorfer M; Steiner S; Schwabl P; Payer BA; Aichelburg MC; Lang G; Grabmeier-Pfistershammer K; Trauner M; Peck-Radosavljevic M; Reiberger T
    J Infect Dis; 2015 Mar; 211(5):729-35. PubMed ID: 25214517
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse.
    de Felipe B; Leal M; Soriano-Sarabia N; Gutiérrez A; López-Cortés L; Molina-Pinelo S; Vallejo A
    J Viral Hepat; 2009 Jan; 16(1):21-7. PubMed ID: 18761604
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection.
    Lindh M; Alestig E; Arnholm B; Eilard A; Hellstrand K; Lagging M; Wahlberg T; Wejstål R; Westin J; Norkrans G
    J Clin Microbiol; 2007 Aug; 45(8):2439-45. PubMed ID: 17581934
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse.
    Labarga P; Barreiro P; Mira JA; Vispo E; Rallón N; Neukam K; Camacho A; Caruz A; Rodriguez-Novoa S; Pinilla J; Rivero A; Benito JM; Pineda JA; Soriano V
    AIDS; 2011 May; 25(8):1131-3. PubMed ID: 21537116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting.
    Gheorghe L; Iacob S; Sporea I; Grigorescu M; Sirli R; Damian D; Gheorghe C; Iacob R
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):23-9. PubMed ID: 17410285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.